Pharmaceuticals
Kintor Pharma Announces First Patient Dosing in Multi-Regional Global Phase II Clinical Trial of ALK-1 Antibody and Nivolumab Combination Therapy for the Treatment of Advanced Hepatocellular Carcinoma
SUZHOU, China, May 4, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing inthe United States of its multi-regional pha...
2022-05-04 20:36
2982
United Imaging Flips the Script on its Events Program for 2022, Reveals Expanded Sales Force and U.S. Growth
Its new AE University also trains new salespeople on the company's unique take on medical imaging purchasing. HOUSTON, May 3, 2022 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, said that it has enhanced its U.S. domestic events progr...
2022-05-03 23:22
2357
Inmagene Receives FDA's IND Clearance for OX40 Antagonist
SAN DIEGO and SHANGHAI and SYDNEY, April 30, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") announces that the U.S. Food and Drug Administration (FDA) has cleared drug candidate IMG-007, a monoclonal antibody against OX40, to proceed to Phase I clinical development. Inmagene is de...
2022-05-01 06:00
4543
IONOVA Announces Clinical Trial Collaboration with MSD to Evaluate INV-1120 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
SHENZHEN, China, April 29, 2022 /PRNewswire/ -- Shenzhen IONOVA Life Science Co., Ltd. announces today it has entered into a clinical trial collaboration agreement with MSD (Merck & Co., Inc., Kenilworth, NJ., USA) to evaluate clinical benefits of INV-1120, IONOVA's EP4 antagonist, in combination...
2022-04-29 20:00
1645
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
- Biotech and Wall Street veteran Mr. Richard Yeh to focus on strategic investor interactions, global alliance management and facilities as COO - Renowned oncology expert Dr. John Hayslip to further accelerate global clinical development of I-Mab's innovative pipeline as CMO SHANGHAI and GAITHE...
2022-04-29 04:01
2452
Formosa Pharmaceuticals and AimMax Therapeutics to Present Phase 2 Trials Results of APP13007 for the Treatment after Cataract Surgery at ARVO 2022 Annual Meeting
TAIPEI, April 28, 2022 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838
2022-04-28 20:00
2306
ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting
SUZHOU, China, and ROCKVILLE, MD, April 27, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that updated results from seven studies involving...
2022-04-28 08:18
2269
China Jo-Jo Drugstores Regains Compliance with Nasdaq Minimum Bid Price Requirement
HANGZHOU, China, April 27, 2022 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that it ...
2022-04-27 20:30
2237
Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
MELBOURNE, Australia, April 27, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the United Kingdom Medicines & Healt...
2022-04-27 19:40
2481
Samsung Biologics Reports First Quarter 2022 Financial Results
* Q1'22 revenue of KRW 511.3 billion increased 96% compared to Q1'21. * Q1'22 operating profit of KRW 176.4 billion increased 137% compared to Q1'21. * Stable business operations and utilization rates across Plants 1, 2, and 3. * Proactive investments into long-term growth, capacity, and su...
2022-04-27 14:42
2574
RVAC Medicines, a CBC-Incubated mRNA Platform Company, Raises US$140 Million to Expand R&D and Manufacturing Capacity
Series B financing led by CBC with participation from Temasek's Pavilion Capital, EDBI and GS Holdings RVAC plans to build R&D center and manufacturing facilities in Singapore and China SINGAPORE, April 26, 2022 /PRNewswire/ -- RVAC Medicines Pte. Ltd. ("RVAC"), an emerging messenger RNA (mRNA)...
2022-04-27 10:00
2975
PharmAbcine Announces Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study
DAEJEON, South Korea, April 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today the positive results from the GLP toxicology study of PMC-403, the Company's novel TIE2-...
2022-04-26 20:30
2197
World Malaria Day: Fosun Pharma's Self-Developed Artemisinin Series Become Symbol of China's Innovative Medicines
Together We Build a Malaria-Free World SHANGHAI, April 25, 2022 /PRNewswire/ -- World Malaria Day on April 25, is an occasion that aims to promote global malaria prevention and control. This year, World Malaria Day is marked under the theme "Harness innovation to reduce the malaria disease burde...
2022-04-25 17:00
3095
Porton Advanced and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Cell Therapy Development for Solid Tumors
SUZHOU, China, April 24, 2022 /PRNewswire/ -- Suzhou Porton Advanced Solutions
Ltd. ('Porton Advanced') and Guizhou Sinorda Biomedicine Co. Ltd ('Sinorda
Biomedicine') today announced a long-term strategic partnership in cell and
gene therapy R&D and platform development.
2022-04-25 11:59
2468
Wallaby Acquires German Neurovascular Leader Phenox to Accelerate Global Expansion
LAGUNA HILLS, Calif. and SHANGHAI and BOCHUM, Germany, April 21, 2022 /PRNewswire/ -- Wallaby Medical ("Wallaby" or the "Company"), a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke, today announced t...
2022-04-21 17:00
1823
Samsung Biologics completes full acquisition of Samsung Bioepis
* Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary * First payment completed funded through paid-in capital * Accelerated growth expected in biosimilars and future novel therapeutics R&D INCHEON,South Korea, April 20, 2022 /PRNewswire/ -- Samsung Biologi...
2022-04-20 14:45
2874
FDA granted CMG901 Fast Track Designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies
CHENGDU, China, April 19, 2022 /PRNewswire/ -- Keymed Biosciences (2162.HK) announced that the U.S. Food and Drug Administration (FDA) granted CMG901 Fast Track Designation as monotherapy for the treatment of unresectable or metastatic gastric and gastroesophageal junction cancer which have relap...
2022-04-20 10:27
2385
ImmVira enters clinical development in combination therapy of MVR-T3011 IT and MEK inhibitor in the U.S.
SHENZHEN, China, April 19, 2022 /PRNewswire/ -- ImmVira announced that, company has reached a cooperation agreement with Roche to establish clinical research partnership recently, to conduct clinicalstudies in the U.S. on the combination therapy of ImmVira's MVR-T3011 IT and Roche's MEK inhibitor...
2022-04-20 08:00
2297
Mediscience Espoir Inc. Looking for OEM Customers, Technical Business Partners and Sales Agents for Oxygen Clathrate Hydrates and Oxygen Solutions
KAWASAKI, Japan, April 19, 2022 /PRNewswire/ -- Mediscience Espoir Inc. announced onApril 19 that it is looking for U.S. partners for oxygen clathrate hydrates and oxygen solutions based on its proprietary technology. The company obtained "Substance Patent" in the United States (US 10,913,037 B2)...
2022-04-19 14:00
2143
GeneQuantum and AIMEDBIO Collaborate on a First-in-Class Antibody -Drug-Conjugate
SUZHOU, China, April 18, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next generation biotherapeutics, has signed an agreement with a Korean biotech company, Aimed Bio Inc., to co-develop a First-in-Class therapeutic an...
2022-04-19 09:00
2217
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 317 media titles]
2026-09-03 23:53
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 311 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36Most Read
Klook Takes Creator Commerce Beyond Influence With Kreator Shops
2026-09-01 11:00
6397
Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
2026-09-02 12:17
5752
